Revolution Research

We are still enrolling for our blepharitis study! Interested?

Reach out to us at 512-721-8352 or [email protected]

Positive news here 👍

Experimental Alzheimer's drug could slow cognitive decline in patients, early results suggest Eli Lilly and Company's experimental intravenous drug donanemab could slow the cognitive decline of patients with Alzheimer's disease, according to early clinical trial results, published in The New England Journal of Medicine on Saturday.

Merry Christmas and Happy Holidays from all of us at Revolution!